Raymond James Maintains Outperform on GenMark Diagnostics, Raises Price Target to $9

Raymond James maintains GenMark Diagnostics (NASDAQ:GNMK) with a Outperform and raises the price target from $8 to $9.

Benzinga · 11/07/2019 17:33

Raymond James maintains GenMark Diagnostics (NASDAQ:GNMK) with a Outperform and raises the price target from $8 to $9.